Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
Ticagrelor was granted FDA approval on 20 July 2011.
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis
- Conditions
- Interventions
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Medical Center of South Arkansas
- Registration Number
- NCT02048085
- Locations
- 🇺🇸
Medical Center of South Arkansas, El Dorado, Arkansas, United States
Paradigm Shift in the Treatment of Patients With ACS
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Yu Bo
- Target Recruit Count
- 250
- Registration Number
- NCT02041650
- Locations
- 🇨🇳
The 2nd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 148
- Registration Number
- NCT02037412
- Locations
- 🇰🇷
Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2015-10-01
- Lead Sponsor
- Inha University Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT02026219
- Locations
- 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of
Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT02022748
- Locations
- 🇺🇸
Research Site, Minneapolis, Minnesota, United States
Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI
- Conditions
- Interventions
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- LifeBridge Health
- Target Recruit Count
- 200
- Registration Number
- NCT02012140
- Locations
- 🇺🇸
Sinai Center for Thrombosis Research, Baltimore, Maryland, United States
Ticagrelor in Severe Community Acquired Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Gordon Bernard
- Target Recruit Count
- 25
- Registration Number
- NCT01998399
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
- Conditions
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13307
- Registration Number
- NCT01994720
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 133
- Registration Number
- NCT01994941
- Locations
- 🇭🇰
Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hospital Authority, Hong Kong, Hong Kong
Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI
- Conditions
- Interventions
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2016-11-09
- Lead Sponsor
- General Hospital of Chinese Armed Police Forces
- Target Recruit Count
- 250
- Registration Number
- NCT01962428
- Locations
- 🇨🇳
General Hospital of Chinese People's Armed Police Forces, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.